Cargando…

Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia

In several randomized studies, remdesivir (RDV) has been reported to shorten the recovery period and improve clinical outcomes in COVID-19 patients, and thus, it is recommended as a standard of care. Nevertheless, controversial reports have been published. The aim of the present study is to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrakis, Vasilis, Rapti, Vasiliki, Akinosoglou, Karolina, Bonelis, Constantinos, Athanasiou, Kalomoira, Dimakopoulou, Vasiliki, Syrigos, Nikolaos K., Spernovasilis, Nikolaos, Trypsianis, Grigoris, Marangos, Markos, Gogos, Charalambos, Papazoglou, Dimitrios, Panagopoulos, Periklis, Poulakou, Garyfallia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611983/
https://www.ncbi.nlm.nih.gov/pubmed/36296225
http://dx.doi.org/10.3390/microorganisms10101949
_version_ 1784819663782281216
author Petrakis, Vasilis
Rapti, Vasiliki
Akinosoglou, Karolina
Bonelis, Constantinos
Athanasiou, Kalomoira
Dimakopoulou, Vasiliki
Syrigos, Nikolaos K.
Spernovasilis, Nikolaos
Trypsianis, Grigoris
Marangos, Markos
Gogos, Charalambos
Papazoglou, Dimitrios
Panagopoulos, Periklis
Poulakou, Garyfallia
author_facet Petrakis, Vasilis
Rapti, Vasiliki
Akinosoglou, Karolina
Bonelis, Constantinos
Athanasiou, Kalomoira
Dimakopoulou, Vasiliki
Syrigos, Nikolaos K.
Spernovasilis, Nikolaos
Trypsianis, Grigoris
Marangos, Markos
Gogos, Charalambos
Papazoglou, Dimitrios
Panagopoulos, Periklis
Poulakou, Garyfallia
author_sort Petrakis, Vasilis
collection PubMed
description In several randomized studies, remdesivir (RDV) has been reported to shorten the recovery period and improve clinical outcomes in COVID-19 patients, and thus, it is recommended as a standard of care. Nevertheless, controversial reports have been published. The aim of the present study is to evaluate the effectiveness of remdesivir in hospitalized patients with COVID-19 pneumonia at three Greek University Departments of Infectious Diseases with homogenous treatment protocols. From September 2020 to February 2021, we retrospectively analyzed adults hospitalized with confirmed SARS-CoV-2 infection and radiological findings of pneumonia, who received remdesivir once daily for five days. Exploratory end points were duration of hospitalization, time of intubation, and death. Overall, 551 patients were included in the study. The optimal cutoff point for the number of days needed after symptom initiation for drug administration associated with better clinical outcome was 7 days. Higher odds for discharge and lower for intubation were observed in patients with treatment initiation ≤7 days (p = 0.052 and p = 0.019, retrospectively) regardless of gender (p = 0.537), hypertension (p = 0.096), dyslipidemia (p = 0.221), diabetes mellitus (p = 0.306), and usage of immunomodulators (p = 0.408). Our study has demonstrated beneficial effects of early treatment with remdesivir (≤7 days from symptom onset) on rates of intubation and probability of discharge.
format Online
Article
Text
id pubmed-9611983
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96119832022-10-28 Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia Petrakis, Vasilis Rapti, Vasiliki Akinosoglou, Karolina Bonelis, Constantinos Athanasiou, Kalomoira Dimakopoulou, Vasiliki Syrigos, Nikolaos K. Spernovasilis, Nikolaos Trypsianis, Grigoris Marangos, Markos Gogos, Charalambos Papazoglou, Dimitrios Panagopoulos, Periklis Poulakou, Garyfallia Microorganisms Article In several randomized studies, remdesivir (RDV) has been reported to shorten the recovery period and improve clinical outcomes in COVID-19 patients, and thus, it is recommended as a standard of care. Nevertheless, controversial reports have been published. The aim of the present study is to evaluate the effectiveness of remdesivir in hospitalized patients with COVID-19 pneumonia at three Greek University Departments of Infectious Diseases with homogenous treatment protocols. From September 2020 to February 2021, we retrospectively analyzed adults hospitalized with confirmed SARS-CoV-2 infection and radiological findings of pneumonia, who received remdesivir once daily for five days. Exploratory end points were duration of hospitalization, time of intubation, and death. Overall, 551 patients were included in the study. The optimal cutoff point for the number of days needed after symptom initiation for drug administration associated with better clinical outcome was 7 days. Higher odds for discharge and lower for intubation were observed in patients with treatment initiation ≤7 days (p = 0.052 and p = 0.019, retrospectively) regardless of gender (p = 0.537), hypertension (p = 0.096), dyslipidemia (p = 0.221), diabetes mellitus (p = 0.306), and usage of immunomodulators (p = 0.408). Our study has demonstrated beneficial effects of early treatment with remdesivir (≤7 days from symptom onset) on rates of intubation and probability of discharge. MDPI 2022-09-30 /pmc/articles/PMC9611983/ /pubmed/36296225 http://dx.doi.org/10.3390/microorganisms10101949 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Petrakis, Vasilis
Rapti, Vasiliki
Akinosoglou, Karolina
Bonelis, Constantinos
Athanasiou, Kalomoira
Dimakopoulou, Vasiliki
Syrigos, Nikolaos K.
Spernovasilis, Nikolaos
Trypsianis, Grigoris
Marangos, Markos
Gogos, Charalambos
Papazoglou, Dimitrios
Panagopoulos, Periklis
Poulakou, Garyfallia
Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
title Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
title_full Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
title_fullStr Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
title_full_unstemmed Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
title_short Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
title_sort greek remdesivir cohort (grec) study: effectiveness of antiviral drug remdesivir in hospitalized patients with covid-19 pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611983/
https://www.ncbi.nlm.nih.gov/pubmed/36296225
http://dx.doi.org/10.3390/microorganisms10101949
work_keys_str_mv AT petrakisvasilis greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT raptivasiliki greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT akinosogloukarolina greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT bonelisconstantinos greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT athanasioukalomoira greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT dimakopoulouvasiliki greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT syrigosnikolaosk greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT spernovasilisnikolaos greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT trypsianisgrigoris greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT marangosmarkos greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT gogoscharalambos greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT papazogloudimitrios greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT panagopoulosperiklis greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia
AT poulakougaryfallia greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia